|  |
| --- |
| **Supplemental Table 1.** Characteristics of 4,807 patients ages ≤ 39 years with classical Hodgkin lymphoma, by race/ethnicity California, 2007 - 2017. |
|   | **White** | **Black** | **Hispanic** | **Asian/PI** |   |
|  | N (%)N= 2298 (49) | N (%)N= 336 (7) | N (%)N= 1611 (33) | N (%)N= 480 (11) | **p-value\*** |
| **Sex** |
|  Male | 1167 (51) | 177 (53) | 834 (52) | 259 ( 54) |  0.525 |
|  Female | 1131 (49) | 159 (47) | 777 (48) | 221 ( 46) |
| **Stage at diagnosis** |
|  Stage I | 204 (9) | 28 (8) | 136 (8) | 43 (9) |  **<0.001** |
|  Stage II | 1210 (53) | 141 (42) | 712 (44) | 241 (50) |
|  Stage III | 428 (19) | 77 (23) | 350 (22) | 89 (19) |
|  Stage IV | 344 (15) | 80 (24) | 323 (20) | 97 (20) |
|  Unknown | 112 (5) | 10 (3) | 90 (6) | 10 (2) |
| **Health insurance** |
|  Private | 1770 (77) | 185 (55) | 819 (51) | 391 (81) | **<0.001** |
|  Public/none | 456 (20) | 148 (44) | 749 (46) | 80 (17) |
|  Unknown | 72 (3) | ~ | 43 (3) | 9 (2) |
| **Neighborhood SES** |
|  Low  | 382 (17) | 157 (47) | 821 (51) | 85 (18) |   |
|  Middle  | 821 (36) | 125 (37) | 554 (34) | 164 (34) |   |
|  High  | 1095 (48) | 54 (16) | 236 (15) | 231 (48) | **<0.001** |
| **B symptoms** |
|  No | 1133 (49) | 138 (41) | 734 (46) | 234 (49) | **<0.001** |
|  Yes | 939 (41) | 178 (53) | 729 (45) | 202 (42) |
|  Unknown | 226 (10) | 20 (6) | 148 (9) | 44 (9) |
| **Histology** |
|  Classical HL, NOS | 514 (22) | 74 (22) | 407 (25) | 114 (24) |  **<0.001** |
|  Mixed cellularity | 146 (6) | 32 (10) | 194 (12) | 30 (6) |
|  Nodular sclerosis | 1638 (71) | 230 (68) | 1010 (63) | 336 (70) |
| **Chemotherapy regimen** |
|  ABVD | 1452 (63) | 209 (62) | 905 (56) | 299 (62) | **<0.001** |
|  ABVEPC | 50 (2) | 10 (3) | 83 (5) | 14 (3) |
|  BEACOPP | 30 (1) | 11 (3) | 46 (3) | 11 (2) |
|  Stanford | 140 (6) | 7 (2) | 43 (3) | 41 (9) |
|  Modified regimens | 339 (15) | 69 (20) | 332 (21) | 76 (16) |
|  Chemo, NOS | 89 ( 4) | 10 (3) | 47 (3) | 13 (3) |
|  Unknown chemo | 198 ( 9) | 20 (6) | 155 (10) | 26 (5) |
| **Radiation therapy** |
|  No radiation/unknown | 1557 ( 68) | 249 (74) | 1168 (73) | 301 (63) | **<0.001** |
|  Radiation | 741 ( 32) | 87 (26) | 443 (27) | 179 (37) |
| **NCI Cancer Center** |
|  No | 1681 (73) | 258 (77) | 1182 (73) | 319 (66) | **0.006** |
|  Yes | 617 (27) | 78 (23) | 429 (27) | 161 (34) |
| **Hematopoietic cell transplantation** |
|  Yes | 214 (9) | 38 (11) | 153 (9) | 53 (11) | 0.117 |
|  No | 2084 ( 91) | 298 (89) | 1458 (91) | 427 (89) |
| **Cause of death** |
| Alive | 2208 (96) | 303 (90) | 1518 ( 94) | 457 (95) | **0.006** |
| Death from lymphoma (HL+NHL) | 62 (3) | 23 (7) | 63 (4) | 17 (4) |
| Death from other cancer | ~ | ~ | ~ | ~ |
| Death from heart/cerebrovascular | ~ | ~ | ~ | ~ |
| Death from other cause | 19 (1) | 7 (2) | 16 (1) | ~ |
| Death from unknown cause | 7 (<1) | ~ | 9 (1) | ~ |
| \*Chi-squared tests were used to assess patient, clinical, and treating facility characteristics associated with race/ethnicityAbbreviations: SES: socioeconomic status; NCI: National Cancer Institute; NOS: not-otherwise specified; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine ABVE-PC: doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone Stanford V: doxorubicin, vinblastine, nitrogen mustard, etoposide, vincristine, bleomycin, prednisone~Data not shown due to too few (<5) events |